NICE publishes guidance on Astellas’ Xospata
The final green light backs NHS use of the drug
Read More
Tag: gilteritinib
NICE backing for Astella’s Xospata
The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia
Read More
Priority review for Astellas’ AML drug
Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Read More
Astellas files experimental AML therapy
Astellas has filed its experimental Acute Myeloid Leukemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer.
Read More
Astellas bags orphan drug status for AML drug
Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
